title: [Oligoprogression].
authors.affiliation: Department of Radiation Oncology, Universitätsspital Zürich (USZ), Rämistrasse 100, 8091 Zurich, Schweiz. Matthias.Guckenberger@usz.ch
authors.forename: Matthias
authors.initials: M
authors.lastname: Guckenberger
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D018450:Disease Progression; D019583:Dose Fractionation, Radiation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000069347:Erlotinib Hydrochloride; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D011446:Prospective Studies; D011799:Quinazolines / Q000627:therapeutic use*; D016634:Radiosurgery / Q000379:methods*; D011879:Radiotherapy Dosage; D019233:Retreatment; D015996:Survival Rate; D017211:Treatment Failure
chemical_list: D011799:Quinazolines; D019788:Fluorodeoxyglucose F18; D000069347:Erlotinib Hydrochloride